What do you think will oral GLP-1s surpass injectables in patient adoption
The logical inference, supported by the established relationship between weight loss magnitude and telogen effluvium incidence, is that retatrutide users face a meaningful risk of temporary hair shedding
Even the National Institutes of Health website will tell you there is no toxicity to B12
Why Commercial Hair Loss Products Dont Fit Every Patient The FDA-approved toolkit for androgenetic alopecia has been the same for years: oral finasteride (1 mg daily), oral dutasteride (0.5 mg, off-label in the U.S.), and topical minoxidil in 2% or 5% solutions or foam
"This product is not intended for human consumption, nor for the diagnosis, treatment, cure, or prevention of any disease
Ongoing bloodwork is essential to monitor hormone levels, red blood cell counts, and overall safety markers